Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.

Autor: Burmeister T; Department of Hematology, Oncology and Tumor Immunology, CVK, Charité-Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. thomas.burmeister@charite.de., Ströh AS; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany., Kehden B; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany., Trautmann H; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany., Meyer C; Diagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe University, Frankfurt, Germany., Marschalek R; Diagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe University, Frankfurt, Germany., Larghero P; Diagnostic Center of Acute Leukemia (DCAL), Institute of Pharmaceutical Biology, Goethe University, Frankfurt, Germany., Schwartz S; Department of Hematology, Oncology and Tumor Immunology, CBF, Charité Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Steffen B; Department of Medicine II, Goethe University, University Hospital, Frankfurt, Germany., Spriewald B; University Hospital Erlangen, Department of Internal Medicine 5, Hematology and Oncology, Erlangen, Germany., Heinicke T; Department of Hematology and Oncology, Otto-von-Guericke University Hospital, Magdeburg, Germany., Jäkel N; Department of Hematology, Oncology, University Hospital, Halle/Saale, Germany., Westermann J; Department of Hematology, Oncology and Tumor Immunology, CVK, Charité-Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Nachtkamp K; Department of Hematology, Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany., Viardot A; Department of Hematology, Oncology, University Hospital Ulm, Ulm, Germany., Topp MS; Department of Hematology, Oncology, University Hospital Würzburg, Würzburg, Germany., Neumann M; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany., Baldus CD; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany., Gökbuget N; Department of Medicine II, Goethe University, University Hospital, Frankfurt, Germany., Brüggemann M; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.

Publikováno v: Leukemia [Leukemia] 2024 Jul; Vol. 38 (7), pp. 1600-1603. Date of Electronic Publication: 2024 Mar 22.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Total body irradiation plus fludarabine compared to busulfan plus fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

Autor: Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, JL, Fegueux, N, Beelen, DW, Rovira, M, Spyridonidis, A, Blaise, D, Bornhauser, M, Karadogan, I, Savani, BN, Nagler, A, Mohty, M, Martin, S, Chevallier, P, Neubauer, A, Damaj, G, Koc, Y, Ganser, A, Collin, M, Yakoub-Agha, I, Ozdogu, H, Araujo, MC, Itala-Remes, M, Orchard, K, Isaksson, C, Bethge, W, Martin, H, Aljurf, M, Faber, E, Caballero, D, Zak, P, Leleu, X, Bay, JO, Rohrlich, PS, Kroger, N, Huynh, A, Schafer-Eckart, K, Milpied, N, Lenhoff, S, Ho, A, Lopez, JLB, Mordini, N, Lioure, B, Halaburda, K, Olivieri, A, Gedde-Dahl, T, Protheroe, R, Tischer, J, Klammer, M, Clausen, J, Potter, V, Ladetto, M, Tilly, H, Deconinck, E, Brecht, A, Muller, LP, Heinicke, T, Carrete, JPT, Bazarbachi, A, Remenyi, P, Rubio, MT, Fanin, R, Perez-Simon, JA, Niels, M, Diez-Martin, JL, Arat, M, Hermine, O, Socie, G, Cornelissen, JJ, Santarone, S, Guyotat, D, Bulabois, CE, Bernasconi, P, Johansson, JE, Vrhovac, R, Greinix, H, Lorenzo, JLL, Apte, S, Craddock, C, Kobbe, G, Zahrani, MA, Dreger, P, Lange, A, Tbakhi, A, Meijer, E, Llamas, CV, Santasusana, JMR, Corradini, P, Benedetti, F, Rambaldi, A, Gandemer, V, Malfuson, JV, Kaare, A, Risitano, A, Petrini, M, Selleri, C, Wu, DP

Publikováno v: Bone Marrow Transplantation
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we compared two "reduced-tox

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3648997c04fa97d9f102964f774d16ce
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4419

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.

Autor: Niederwieser D; University Leipzig, 04106, Leipzig, Germany. dietger.niederwieser@medizin.uni-leipzig.de.; Lithuanian University of Health Sciences, Kaunas, Lithuania. dietger.niederwieser@medizin.uni-leipzig.de.; Aichi Medical University, Nagakute, Japan. dietger.niederwieser@medizin.uni-leipzig.de., Lang T; Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig Maximilian Universität München, München, Germany., Krahl R; University Leipzig, 04106, Leipzig, Germany., Heinicke T; Dept. Hematology and Oncology, Otto-Von-Guericke-University, Magdeburg, Germany., Maschmeyer G; Dept. Hematology, Oncology and Palliative Care, Klinikum Ernst Von Bergmann, Potsdam, Germany., Al-Ali HK; Department of Internal Medicine IV, Oncology/Hematology, Krukenberg Cancer-Center, University Hospital Halle (Saale), Halle, Germany., Schwind S; University Leipzig, 04106, Leipzig, Germany., Jentzsch M; University Leipzig, 04106, Leipzig, Germany., Cross M; University Leipzig, 04106, Leipzig, Germany., Kahl C; Dept. Internal Medicine, Clinic III - Hematology, Oncology and Palliative Care, Rostock University Medical Center, Rostock, Germany.; Dept. Hematology, Oncology and Palliative Care, Klinikum Magdeburg gGmbH, Magdeburg, Germany., Wolf HH; Dept. Hematology and Oncology, University Hospital, Halle, Germany., Sayer H; Medizinische Klinik (Hämatologie, Stammzelltransplantation, Onkologie), Helios Klinikum Erfurt, Erfurt, Germany., Schulze A; University Leipzig, 04106, Leipzig, Germany., Dreger P; Medical Department V, University Hospital, Heidelberg, Germany., Hegenbart U; Medical Department V, University Hospital, Heidelberg, Germany., Krämer A; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University, Heidelberg, Germany., Junghanss C; Department of Medicine, Clinic III (Hematology, Oncology, Palliative Medicine), Rostock University Medical Center, Rostock, Germany., Mügge LO; Innere Medizin III (Hämatologie, Onkologie Und Palliativmedizin), Hospital Zwickau, Germany., Hähling D; Dept. Hematology and Oncology, Klinikum Schwerin, Schwerin, Germany., Hirt C; Innere Medizin C, Universitätsmedizin Greifswald, Sauerbruchstraße, 17475, Greifswald, Germany., Späth C; Innere Medizin C, Universitätsmedizin Greifswald, Sauerbruchstraße, 17475, Greifswald, Germany., Peter N; Medizinische Klinik, Carl-Thieme-Klinikum GmbH, Cottbus, Germany., Opitz B; St. Elisabeth Und St, Barbara Hospital Halle (Saale), Halle, Germany., Florschütz A; Klinikum Dessau, Dessau, Germany., Reifenrath K; Klinikum, Zittau, Germany., Zojer N; 1St Medical Department, Center for Oncology and Hematology & Palliative Care, Klinik Ottakring, Vienna, Austria., Scholl S; Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany., Pönisch W; University Leipzig, 04106, Leipzig, Germany., Heyn S; University Leipzig, 04106, Leipzig, Germany., Vucinic V; University Leipzig, 04106, Leipzig, Germany., Hochhaus A; Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany., Aul C; Klinik Für Hämatologie Und Onkologie, St. Johannes Hospital, Duisburg, Germany., Giagounidis A; Klinik Für Hämatologie Und Onkologie, St. Johannes Hospital, Duisburg, Germany.; Dept. Oncology, Hematology and Palliative Care, Marienhospital Düsseldorf, Düsseldorf, Germany., Balleisen L; Dept. Medicine II, Evangelisches Krankenhaus Hamm, Hamm, Germany., Oldenkott B; Dept. Hematology and Oncology, St. Hedwig Krankenhaus Berlin, Berlin, Germany., Staib P; Dept. Hematology/Oncology, St. Antonius Krankenhaus Eschweiler, Eschweiler, Germany., Kiehl M; Dept. Medicine I, Klinikum Frankfurt/Oder, FrankfurtOder, Germany., Schütte W; Dept. Internal Medicine II, Krankenhaus Martha-Maria, Halle, Germany., Naumann R; Dept. Hematology, Oncology and Palliative Care, St. Marien-Krankenhaus Siegen, Siegen, Germany., Eimermacher H; Dept. Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany., Dörken B; Dept. Hematology and Oncology, Charité Campus Virchow, Berlin, Germany., Sauerland C; Institute of Biometry and Clinical Research, University Hospital Münster, Münster, Germany., Lengfelder E; IIIrd Medical Dept, University Hospital of Mannheim, Mannheim, Germany., Hiddemann W; IIIrd Medical Dept, University Hospital Großhadern, Munich, Germany., Wörmann B; Division of Hematology, Oncology and Tumour Immunology, Department of Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.; Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Berlin, Germany., Müller-Tidow C; Dept. of Medicine A, University Hospital of Münster, Münster, Germany.; Dept. of Medicine V, University Hospital of Heidelberg, Heidelberg, Germany., Serve H; Dept. of Medicine A, University Hospital of Münster, Münster, Germany.; Department of Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany., Schliemann C; Dept. of Medicine A, University Hospital of Münster, Münster, Germany., Hehlmann R; Mannheim, University of Heidelberg, Mannheim, Germany.; European LeukemiaNet, Weinheim, Germany., Berdel WE; Dept. of Medicine A, University Hospital of Münster, Münster, Germany., Pfirrmann M; Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig Maximilian Universität München, München, Germany., Krug U; Dept. of Medicine A, University Hospital of Münster, Münster, Germany.; Dept. of Medicine 3, Klinikum Leverkusen, Leverkusen, Germany., Hoffmann VS; Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig Maximilian Universität München, München, Germany.

Publikováno v: Annals of hematology [Ann Hematol] 2023 Mar; Vol. 102 (3), pp. 547-561. Date of Electronic Publication: 2023 Jan 25.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.